What is new in IBD, Crohn’s disease and ulcerative colitis
Current evidence to clinical practice – improving QoL in IBD: contemporary biologic therapy strategies focusing on efficacy/safety of vedolizumab in biologic-naïve/prior anti-TNF failure in ulcerative colitis and Crohn’s disease
You will learn about:
Current developments in the care of patients with inflammatory bowel disease, with a primary focus on vedolizumab therapy.
To access this module, please register or login: